Sanibel Captiva Trust Company Inc. Sells 980 Shares of Becton, Dickinson and Company (NYSE:BDX)

Sanibel Captiva Trust Company Inc. trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 11.3% during the first quarter, Holdings Channel reports. The firm owned 7,728 shares of the medical instruments supplier’s stock after selling 980 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in Becton, Dickinson and Company were worth $1,770,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Bank of Jackson Hole Trust acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $25,000. REAP Financial Group LLC increased its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 55 shares during the period. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $29,000. Picton Mahoney Asset Management lifted its position in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $34,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

BDX opened at $174.21 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a market cap of $49.93 billion, a P/E ratio of 28.94, a PEG ratio of 1.63 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The firm has a 50-day moving average of $184.92 and a 200 day moving average of $214.07.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.17 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.39%. Becton, Dickinson and Company’s payout ratio is 79.39%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Citigroup lowered Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their price objective for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price target on the stock. in a research report on Friday, May 2nd. Piper Sandler lowered shares of Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Wells Fargo & Company lowered Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. Finally, Stifel Nicolaus decreased their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $219.22.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Richard Byrd sold 459 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the transaction, the executive vice president now directly owns 6,952 shares in the company, valued at approximately $1,598,960. This represents a 6.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,104 shares of company stock valued at $399,675. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.